Risankizumab resolves extraintestinal manifestations in CD

A pooled analysis of 3 trials investigating risankizumab in participants with Crohn’s disease (CD) demonstrated that induction therapy with this agent improved the resolution of extraintestinal manifestations (EIMs) compared with placebo. Furthermore, risankizumab maintenance therapy contributed to sustaining the resolution of EIMs.

Prof. Subrata Ghosh (Cork University College, Ireland) conducted a post-hoc pooled analysis of the ADVANCE (NCT03105128) and MOTIVATE (NCT03104413) induction trials and FORTIFY (NCT03105102) maintenance study to assess the effect of risankizumab on EIMs in participants with moderate-to-severe CD as compared with placebo [1]. At baseline, 622 participants with EIMs were included. “Importantly, most participants had failed on at least 1 biologic therapy,” emphasised Prof. Ghosh. The most common EIMs were peripheral arthropathy, anaemia, and axial arthropathy.

After 12 weeks of induction therapy, the percentage of participants with resolution of EIMs was 34.5% in the risankizumab group and 22.5% in the placebo group (P<0.05). Looking at specific EIMs, axial arthropathy was resolved in 50% and 30.8% of the participants in the risankizumab group and placebo group, respectively (P<0.05). Similar trends were observed for anaemia (37.4% vs 22.4%; P<0.05) and peripheral arthropathy (39.8% vs 31.2%; P>0.05), although the latter did not reach statistical significance.

In the maintenance period, at week 52, the percentage of participants with resolution of any EIM was 52.2% in the risankizumab 360 mg group, 41.7% in the risankizumab 180 mg group, and 36.3% in the placebo group. Finally, in participants who resolved EIMs following induction therapy, the corresponding rates at week 52 were 71.9%, 45.9%, and 45.0%, respectively.

The current post-hoc analysis showed that risankizumab is more efficacious than placebo in resolving EIMs and sustaining the resolution of EIMs during maintenance therapy.

1. 
   
   1. Ghosh S, et al. Effect of risankizumab treatment on extraintestinal manifestations in patients with moderate to severe Crohn’s disease: results from the ADVANCE, MOTIVATE, and FORTIFY studies. OP037, UEG Week 2023, 14–17 October, Copenhagen, Denmark.

Copyright ©2023 Medicom Medical Publishers



Posted on 7 December, 20238 April, 2024